Beauty Health (SKIN) Projected to Post Quarterly Earnings on Thursday

Key Points

• Beauty Health is expected to report its Q2 2025 earnings on August 7, with analysts predicting an earnings per share of ($0.06) and revenue of $74.67 million.
• The company recently reported Q1 earnings of ($0.08) per share, surpassing expectations, and had revenue of $69.60 million, which was above the estimated $63.88 million.
• Goldman Sachs has downgraded its price target for Beauty Health's stock from $1.50 to $1.25, and currently, 93.26% of the company's stock is held by institutional investors.

Beauty Health (NASDAQ:SKIN - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results after the market closes on Thursday, August 7th. Analysts expect Beauty Health to post earnings of ($0.06) per share and revenue of $74.67 million for the quarter. Beauty Health has set its FY 2025 guidance at EPS and its Q2 2025 guidance at EPS.

Beauty Health (NASDAQ:SKIN - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.05. The firm had revenue of $69.60 million for the quarter, compared to the consensus estimate of $63.88 million. Beauty Health had a negative net margin of 11.94% and a negative return on equity of 67.91%. On average, analysts expect Beauty Health to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Beauty Health Stock Down 0.6%

SKIN stock traded down $0.01 during mid-day trading on Friday, hitting $1.53. 540,357 shares of the company were exchanged, compared to its average volume of 665,360. The company has a debt-to-equity ratio of 12.01, a quick ratio of 6.43 and a current ratio of 7.47. The firm has a market cap of $192.76 million, a P/E ratio of -3.73 and a beta of 1.20. The firm's 50 day simple moving average is $1.77 and its 200 day simple moving average is $1.52. Beauty Health has a 1-year low of $0.78 and a 1-year high of $2.38.

Institutional Trading of Beauty Health

A hedge fund recently raised its stake in Beauty Health stock. Goldman Sachs Group Inc. lifted its position in The Beauty Health Company (NASDAQ:SKIN - Free Report) by 5.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 665,706 shares of the company's stock after buying an additional 31,880 shares during the quarter. Goldman Sachs Group Inc. owned about 0.53% of Beauty Health worth $892,000 as of its most recent SEC filing. 93.26% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Canaccord Genuity Group dropped their target price on shares of Beauty Health from $1.50 to $1.25 and set a "hold" rating on the stock in a report on Monday, May 5th. Stifel Nicolaus lifted their price objective on shares of Beauty Health from $3.00 to $4.00 and gave the company a "hold" rating in a report on Friday.

About Beauty Health

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.